Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.
254 Results
Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.
Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
Biodesix announces the U.S. commercial availability of VeriStrat.
Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.
Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).